Nicox
Nicox is a biopharmaceutical company based in Sophia Antipolis, France, focused on developing and commercializing nitric oxide (NO)-donating drugs for various health conditions, particularly inflammation and cardio-metabolic diseases. The company's primary product candidates include Naproxcinod, which is in Phase III trials for osteoarthritis, and NCX 6560, an NO-donating compound in Phase I trials targeting cardiovascular diseases. Additionally, Nicox's portfolio features several drugs in clinical development, such as PF-03187207 for glaucoma, TPI 1020 for respiratory disorders, and NCX 1510 for allergic rhinitis, all in Phase II trials. The company's pipeline also includes NCX 1047, aimed at treating skin disorders, and various NO-donors for conditions like diabetic retinopathy and hypertension. Collaborations with organizations such as Orexo AB, Pfizer Inc., and Merck & Co. further enhance its research and development capabilities. Founded in 1996, Nicox is dedicated to advancing innovative therapeutic solutions to improve patient outcomes in ophthalmology and beyond.
Top Stages
3 past transactions
Doliage
Acquisition in 2014
Doliage is a pharmaceutical company specializing in ophthalmic products, particularly focusing on conditions such as dry eye syndrome, glaucoma, and eye infections. Established in 2004, Doliage has been at the forefront of developing medical food supplements specifically tailored for ophthalmology. The company was the first to combine lutein and omega-3 in its formulations, setting a standard in micronutrition for eye health. In 2009, Doliage expanded its product line to include B vitamins, further enhancing its offerings in dietary supplements. All products are manufactured in a pharmaceutical environment, ensuring high quality and compliance with industry standards. Through its commitment to staying updated with the latest scientific research, Doliage maintains a comprehensive portfolio of dietary supplements and prescription pharmaceuticals, including Euronac for corneal healing and Tobrabact Ge, an ocular antibiotic.
Aciex Therapeutics
Acquisition in 2014
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.
EuPharmed
Acquisition in 2013
EuPharmed s.r.l. is an Italian pharmaceutical company specializing in the development and marketing of various healthcare products, with a particular focus on the ophthalmological sector. The company's portfolio includes pharmaceutical products, over-the-counter items, parapharmaceuticals, nutraceuticals, and medical devices designed to treat a range of ocular pathologies and ophthalmic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.